FindTrial
Sign In

Xarelto 15 mg film-coated tablets

DRUG5 trials

Sponsors

Centre Hospitalier Universitaire De Saint Etienne, Royal College Of Surgeons In Ireland, Royal College Of Surgeons In Ireland, Amsterdam UMC, Anthos Therapeutics Inc., University Of Ottawa Heart Institute

Conditions

Acute Venous ThromboembolismAtrial FibrillationAtrial fibrillationCoronary artery diseasePercutaneous coronary interventionRisk of stroke by Atrial Fibrillationacute venous thromboembolism event

Phase 2

A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation (AZALEA)
Active, not recruitingCTIS2023-509066-38-00
Anthos Therapeutics Inc.Atrial Fibrillation
Start: 2021-04-16Target: 896Updated: 2025-10-15

Phase 3

Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE
RecruitingCTIS2022-500974-33-00
Centre Hospitalier Universitaire De Saint Etienneacute venous thromboembolism event
Start: 2023-08-12Target: 1400Updated: 2025-04-25

Phase 4

COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
CompletedCTIS2023-504179-26-00
Royal College Of Surgeons In Ireland, Royal College Of Surgeons In IrelandAcute Venous Thromboembolism
Start: 2024-07-19End: 2025-04-10Target: 24Updated: 2024-07-15
Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
RecruitingCTIS2023-508904-39-00
Amsterdam UMCAtrial fibrillation, Coronary artery disease, Percutaneous coronary intervention
Start: 2024-08-22Target: 50Updated: 2024-06-21
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
CompletedCTIS2024-518736-37-00
University Of Ottawa Heart InstituteRisk of stroke by Atrial Fibrillation
Start: 2018-01-12End: 2025-06-17Target: 282Updated: 2024-11-19